MTARC1 and metabolic dysfunction-associated steatohepatitis: To understand whether liver-specific loss of mARC1 can also confer protection from the development of MASH and liver fibrosis, we used a GalNAc-conjugated hepatocyte-targeting siRNA to knockdown Mtarc1 specifically in hepatocytes in a therapeutic paradigm in mice fed a GAN diet for 16 weeks.